Detalhe da pesquisa
1.
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
Am J Transplant
; 22(8): 2083-2088, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278260
2.
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
Am J Transplant
; 22(11): 2682-2688, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35801839
3.
Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.
Nephrology (Carlton)
; 27(11): 901-905, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36047901
4.
Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.
Am J Transplant
; 22(7): 1925-1926, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015924
5.
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients.
Clin Transplant
; 36(3): e14594, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032413
6.
Managing the significant drug-drug interaction between tacrolimus and letermovir in solid organ transplant recipients.
Clin Transplant
; 35(3): e14213, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438781
7.
Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients.
Transplantation
; 106(10): e463-e464, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939386